ID 8411
File
Authors
Koyama, Satoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB
Miyake, Naritomo Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Fujiwara, Kazunori Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Morisaki, Tsuyoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine
Fukuhara, Takahiro Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Kitano, Hiroya Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine / Center for Head and Neck Surgery, Kusatsu General Hospital
Takeuchi, Hiromi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Keywords
Lenvatinib
Anaplastic thyroid cancer
Chemotherapy
Hypothyroidism
Tyrosine kinase inhibitor
Abstract
Background: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine. Knowledge of the efficacy and safety of lenvatinib in patients with anaplastic thyroid cancer (ATC) is limited. Tyrosine kinase inhibitors frequently cause hypothyroidism; the incidence of hypothyroidism with lenvatinib is unclear. Objectives: We conducted a retrospective study to investigate the efficacy and safety of lenvatinib in ATC. Methods: Five patients with unresectable ATC were enrolled. Lenvatinib 24 mg once daily was administered until disease progression, unmanageable toxicity, withdrawal, or death occurred. We retrospectively analyzed objective response rate (ORR), time to progression (TTP), overall survival, and safety. Results: Three of the five patients (60%) had a partial response, and two (40%) had stable disease. ORR was 60%. Median TTP was 88 days, and overall survival was 165 days. Hypothyroidism was a common treatment-related adverse effect; four patients (80%) had hypothyroidism of any grade. These four patients had not undergone total thyroidectomy prior to lenvatinib administration, and the other patient had undergone total thyroidectomy. Treatment-related adverse effects of any grade were hypertension in 80% of patients, diarrhea in 40%, fatigue in 80%, and decreased appetite in 80%. Conclusions: Lenvatinib is an effective treatment and may improve the prognosis of unresectable ATC. Four of five patients had hypothyroidism, which may have been associated with treatment-induced injury of the thyroid gland. There were many treatment-related adverse effects, most of which were manageable by dose modification and medical therapy.
Publisher
S. Karger AG
Content Type
Journal Article
Link
ISSN
22350640
EISSN
22350802
Journal Title
EUROPEAN THYROID JOURNAL
Current Journal Title
EUROPEAN THYROID JOURNAL
Volume
7
Issue
3
Start Page
139
End Page
144
Published Date
2018-06
Publisher-DOI
Text Version
Author
Rights
© 2018 European Thyroid Association Published by S. Karger AG, Basel. This is the peer-reviewed but unedited manuscript version of the following article: Eur Thyroid J 2018;7:139-144. (doi: 10.1159/000485972). The final, published version is available at http://www.karger.com/?doi=10.1159/000485972
Citation
Koyama Satoshi, Miyake Naritomo, Fujiwara Kazunori, et al. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction. EUROPEAN THYROID JOURNAL. 2018. 7(3). 139-144. doi:10.1159/000485972
Department
Faculty of Medicine/Graduate School of Medical Sciences/University Hospital
Language
English
Web of Science Key ut
WOS:000438872900005